Form 4: Vera Therapeutics Director Acquires Stock Options

Beth C. Seidenberg, a Director at Vera Therapeutics, Inc., acquired stock options for 17,084 shares of Class A Common Stock.

Summary

• Beth C. Seidenberg, a Director of Vera Therapeutics, Inc., was granted stock options on May 21, 2026.
• The options are for 17,084 shares of Class A Common Stock with an exercise price of $34.35 per share.
• These options are set to expire on May 20, 2036.
• The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, provided continuous service is maintained.
• Vesting will also occur in full upon a change in control, subject to continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it solely reports a standard stock option grant to a director, which is a routine event and does not provide new financial performance data or strategic updates.

Positives

• Director Beth C. Seidenberg has acquired stock options, indicating continued commitment and potential alignment with shareholder interests.
• The stock options have a long expiration date of May 20, 2036, providing a significant potential upside over time.
• Vesting provisions include acceleration upon a change in control, which can benefit the reporting person in such scenarios.

Negatives

• The filing does not disclose any negative financial or operational information; it solely reports a transaction by a director.
• The exercise price of $34.35 per share suggests that the stock price would need to significantly increase for these options to be profitable.

Risks

• The primary risk associated with these options is that the company's stock price may not exceed the exercise price of $34.35, rendering the options worthless.
• The vesting is contingent on continued service, meaning any departure from the company before vesting could result in forfeiture of the unvested options.

Future Outlook

The future outlook for the stock options is dependent on the company's performance and stock price appreciation. Vesting is tied to continued service and potential change in control events.

Industry Context

StockSavvy.ai notes that the grant of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, serving as a long-term incentive to align management's interests with those of shareholders and to retain key talent.

Related Party Transactions

• The acquisition of stock options by Director Beth C. Seidenberg represents a transaction between the company and a related party (a director).

Stakeholder Impact

• Shareholders: The grant of options dilutes existing ownership slightly but aligns director incentives with potential future stock price appreciation.
• Employees: The grant may signal confidence in the company's future prospects, potentially boosting morale.
• Management: Provides a significant incentive for the director to contribute to the company's success and potentially a reward in case of a change in control.

Next Steps

• The reporting person must maintain continuous service to meet vesting requirements.
• The options may vest fully upon a change in control of the company.
• Vesting is scheduled to occur in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting.

Key Dates

Keywords

Vera Therapeutics, VERA, Form 4, Stock Options, Director, Beneficial Ownership, Securities Exchange Act, Beth C. Seidenberg